Frontier Communications

Frontier Medicines is a precision medicine company focused on developing small-molecule therapeutics against "undruggable" targets. The company utilizes a proprietary platform that combines chemoproteomics, covalent chemistry, and machine learning to identify novel binding pockets on disease-causing proteins. Its lead candidate, FMC-376, is a dual inhibitor of both the active and inactive forms of KRAS G12C, designed to overcome resistance seen with first-generation inhibitors. Frontier is advancing a pipeline of oncology programs and has established a strategic collaboration with AbbVie. The company is headquartered in South San Francisco and is backed by leading life science investors.